Trial Profile

Randomized Phase II Study of Adjuvant WT-1 Analog Peptide Vaccine in Patients With Malignant Pleural Mesothelioma (MPM) After Completion of Combined Modality Therapy.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 14 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Galinpepimut S (Primary) ; Montanide ISA-51; Sargramostim
Indications Malignant-mesothelioma
Focus Therapeutic Use

Most Recent Events

09 Oct 2024 Primary endpoints has been amended. Actual Primary Completion Date changed from 25 Jul 2017 to 30 Nov 2016. Actual number of patients has been changed from 40 to 41.
08 Aug 2017 According to a joint media release by Galena Biopharma Inc. and SELLAS Life Sciences Group Ltd., status changed from active, no longer recruiting to completed.
04 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com